1Doyle ME, Egan JM. Mechanisms of glucagon-like peptidel in the pancreas [ J ]. Pharmacol Ther,2007,113 ( 3 ) :546-593. 被引量：1
2Kim W, Egan JM. The role of inm'etins in glucose homeostasis and diabetes treatment [J]. Pharmacol Rev,2008,60 (4) :470-512. 被引量：1
3Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets[ J]. Endocrinology,2003,144:5149-5158. 被引量：1
4Drucker DJ, Philippe J, Mojsov S, et al. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line[ J]. Proc Natl Acad Sei USA, 1987,84(10) :3434- 3438. 被引量：1
5Buteau J, Roduit R, Susini S, et al. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 ( PDX- 1 ) DNA binding activity in beta ( INS-1 ) -cells [ J ]. Diabetologia, 1999,42 ( 7 ) : 856 -864. 被引量：1
6Zhao T, Parikh P, Bhashyam S, et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts [ J ]. J Pharmacol Exp Ther, 2006,317:1106-1113. 被引量：1
2HUSSAIN A, CLAUSSEN B, RAMACHANDRAN A. et al. Prevention of type 2 diabetes : A review [ J ]. Diabetes Res Clin Prac,2007,76930 (3) :317-326. 被引量：1
3LINNEBJER G H, KOTHARE P A,PARK S, et al. Effect of renal impairment on the pharmacokinetics of exenatide [ J]. Br J Clin Pharmacol,2007,64(3) :317-327. 被引量：1
4ROUBICEK T, MRA Z M, BARTLOVA M, et al. The influ- ence of 6-months treatment with exenatide on type 2 diabetes mellitus compensation , anthropometric and biochemical parameters [ J]. Vnitr Lek, 2010,56 ( 1 ) : 15- 20. 被引量：1
5VILSBOLL T. Liraglutide:a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus [ J ]. Expert Opin Investig Drugs,2007,16 (2) :231-237. 被引量：1
6Tomoyuki I, Masato Y, Masahiko I. Sitagliptin as a novel treatment a- gent for non-alcoholic Fatty liver disease patients with type 2 diabe- tes mellitus [ J ]. Hepato - gastroenterology, 2011,58 ( 112 ) : 2103 - 2105. 被引量：1
7Tomoyuki I, Wataru T, Masato Y. Non- alcoholic fatty liver disease adversely affects the glycemic control afforded by sitagliptin [ J ]. Hepato-gastroenterology ,2011,59 ( 12 ) : 1522-1525. 被引量：1
8Fujiwara H, Fukuoka M, Yasuda K, et al. Cytokines stimulate dipep- tidy] peptidase-IV expression on human luteinizing granulosa cells [ J ]. Journal of Clinical Endocrinology & Metabolism, 1994,79 (4) :1007-1011. 被引量：1
10Aschner P, Katzerff HL, Guo H, et al. Efficacy and safety of mono- therapy of sitagliptin compared with metformin in patients with type 2 diabetes [ J ]. Diabetes Obes Metab ,2010,12 (3) :252-261. 被引量：1
